{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:51:49Z","timestamp":1791474709093,"version":"4.3.4"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.blre.2022.100992","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T17:34:14Z","timestamp":1658597654000},"page":"100992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Follicular lymphoma: The long and winding road leading to your cure?"],"prefix":"10.1016","volume":"57","author":[{"given":"Max J.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.blre.2022.100992_bb0005","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood."},{"issue":"20","key":"10.1016\/j.blre.2022.100992_bb0010","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJM198211113072002","article-title":"Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin\u2019s lymphoma","volume":"307","author":"Yunis","year":"1982","journal-title":"N Engl J Med"},{"issue":"4720","key":"10.1016\/j.blre.2022.100992_bb0015","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1126\/science.3929382","article-title":"The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining","volume":"229","author":"Tsujimoto","year":"1985","journal-title":"Science."},{"issue":"7","key":"10.1016\/j.blre.2022.100992_bb0020","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.V73.7.1759.1759","article-title":"Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas","volume":"73","author":"Ngan","year":"1989","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2022.100992_bb0025","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood.V80.4.879.879","article-title":"Bcl-2 initiates a new category of oncogenes: regulators of cell death","volume":"80","author":"Korsmeyer","year":"1992","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2022.100992_bb0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0092-8674(89)90174-8","article-title":"bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation","volume":"57","author":"McDonnell","year":"1989","journal-title":"Cell."},{"issue":"3","key":"10.1016\/j.blre.2022.100992_bb0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2008.07353.x","article-title":"Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma","volume":"143","author":"Pro","year":"2008","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2022.100992_bb0040","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.blre.2022.100992_bb0045","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2022.100992_bb0050","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2022.100992_bb0055","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2022.100992_bb0060","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.blre.2022.100992_bb0065","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood."},{"issue":"6189","key":"10.1016\/j.blre.2022.100992_bb0070","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","article-title":"Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells","volume":"335","author":"Vaux","year":"1988","journal-title":"Nature."},{"issue":"11","key":"10.1016\/j.blre.2022.100992_bb0075","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1084\/jem.20061292","article-title":"Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis","volume":"203","author":"Roulland","year":"2006","journal-title":"J Exp Med"},{"issue":"19","key":"10.1016\/j.blre.2022.100992_bb0080","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.1073\/pnas.91.19.8910","article-title":"BCL2 translocation frequency rises with age in humans","volume":"91","author":"Liu","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.blre.2022.100992_bb0085","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.celrep.2015.08.036","article-title":"DNA methylation dynamics of germinal center B cells are mediated by AID","volume":"12","author":"Dominguez","year":"2015","journal-title":"Cell Rep"},{"issue":"7360","key":"10.1016\/j.blre.2022.100992_bb0090","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.blre.2022.100992_bb0095","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.blre.2022.100992_bb0100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.blre.2022.100992_bb0105","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.blre.2022.100992_bb0110","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"B\u00f6d\u00f6r","year":"2013","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2022.100992_bb0115","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2022.100992_bb0120","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood.V99.7.2562","article-title":"Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma","volume":"99","author":"Zhu","year":"2002","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2022.100992_bb0125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","article-title":"Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma","volume":"129","author":"Krysiak","year":"2017","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.100992_bb0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ng.3473","article-title":"Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma","volume":"48","author":"Okosun","year":"2016","journal-title":"Nat Genet"},{"issue":"22","key":"10.1016\/j.blre.2022.100992_bb0135","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1158\/0008-5472.CAN-10-2460","article-title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.blre.2022.100992_bb0140","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.blre.2022.100992_bb0145","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.cell.2011.09.035","article-title":"The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma","volume":"147","author":"Oricchio","year":"2011","journal-title":"Cell."},{"issue":"21","key":"10.1016\/j.blre.2022.100992_bb0150","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1182\/blood.2020009855","article-title":"Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma","volume":"137","author":"Haebe","year":"2021","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2022.100992_bb0155","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41375-018-0043-y","article-title":"Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma","volume":"32","author":"Araf","year":"2018","journal-title":"Leukemia."},{"issue":"21","key":"10.1016\/j.blre.2022.100992_bb0160","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2022.100992_bb0165","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-021-00521-4","article-title":"Lack of intrafollicular memory CD4+T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma","volume":"11","author":"Mondello","year":"2021","journal-title":"Blood Cancer J"},{"issue":"34","key":"10.1016\/j.blre.2022.100992_bb0170","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.18.02365","article-title":"Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration","volume":"37","author":"Tobin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.blre.2022.100992_bb0175","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1158\/0008-5472.CAN-15-0589","article-title":"Follicular B lymphomas generate regulatory T cells via the ICOS\/ICOSL pathway and are susceptible to treatment by anti-ICOS\/ICOSL therapy","volume":"76","author":"Le","year":"2016","journal-title":"Cancer Res"},{"issue":"34","key":"10.1016\/j.blre.2022.100992_bb0180","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","article-title":"Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients","volume":"24","author":"Alvaro","year":"2006","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.blre.2022.100992_bb0185","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC cancer agency and the lymphoma study association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.blre.2022.100992_bb0190","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1038\/s41375-021-01201-9","article-title":"The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma","volume":"35","author":"Valero","year":"2021","journal-title":"Leukemia."},{"issue":"23","key":"10.1016\/j.blre.2022.100992_bb0195","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2022.100992_bb0200","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.blre.2022.100992_bb0205","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.100992_bb0210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2022.100992_bb0215","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood."},{"issue":"27","key":"10.1016\/j.blre.2022.100992_bb0220","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.blre.2022.100992_bb0225","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.100992_bb0230","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2019-130208","article-title":"Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy","volume":"134","author":"Jurinovic","year":"2019","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.100992_bb0235","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.16159","article-title":"M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy","volume":"188","author":"Lockmer","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2022.100992_bb0240","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.blre.2022.100992_bb0245","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/bloodadvances.2016000786","article-title":"Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets","volume":"1","author":"Bolen","year":"2017","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.blre.2022.100992_bb0250","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood.2020008119","article-title":"Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma","volume":"137","author":"Bolen","year":"2021","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2022.100992_bb0255","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2022.100992_bb0260","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.blre.2022.100992_bb0265","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3324\/haematol.2020.275958","article-title":"Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"106","author":"Duell","year":"2021","journal-title":"Haematologica."},{"issue":"5","key":"10.1016\/j.blre.2022.100992_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"The Lancet Haematol"},{"issue":"15_suppl","key":"10.1016\/j.blre.2022.100992_bb0275","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2018.36.15_suppl.7507","article-title":"Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed\/refractory (r\/r) FL and DLBCL","volume":"36","author":"Sehn","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2022.100992_bb0280","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1016\/S2352-3026(21)00311-2","article-title":"Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b\/2 study","volume":"8","author":"Diefenbach","year":"2021","journal-title":"The Lancet Haematol"},{"issue":"18","key":"10.1016\/j.blre.2022.100992_bb0285","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and Rituximab in non-Hodgkin\u2019s Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.blre.2022.100992_bb0290","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2022.100992_bb0295","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2022.100992_bb0300","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia."},{"issue":"10","key":"10.1016\/j.blre.2022.100992_bb0305","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.blre.2022.100992_bb0310","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood."},{"issue":"16","key":"10.1016\/j.blre.2022.100992_bb0315","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"31","key":"10.1016\/j.blre.2022.100992_bb0320","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.blre.2022.100992_bb0325","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100992_bb0330","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-134363","article-title":"Patients with relapsed\/refractory marginal zone lymphoma in the MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance","volume":"136","author":"Coleman","year":"2020","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2022.100992_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"The Lancet Haematol"},{"issue":"10","key":"10.1016\/j.blre.2022.100992_bb0340","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.blre.2022.100992_bb0345","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1158\/1078-0432.CCR-20-1345","article-title":"A three-arm randomized phase II study of bendamustine\/rituximab with bortezomib induction or lenalidomide continuation in untreated follicular lymphoma: ECOG-ACRIN E2408","volume":"26","author":"Evens","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2022.100992_bb0350","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/blood-2019-129422","article-title":"Results of a Phase II study of obinutuzumab in combination with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL)","volume":"134","author":"Nastoupil","year":"2019","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100992_bb0355","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-134120","article-title":"Treatment and outcome of patients with follicular lymphoma relapsed or progressed after frontline lenalidomide and rituximab","volume":"136","author":"Strati","year":"2020","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2022.100992_bb0360","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1128\/MCB.22.24.8580-8591.2002","article-title":"Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex","volume":"22","author":"Jou","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.blre.2022.100992_bb0365","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell."},{"issue":"2","key":"10.1016\/j.blre.2022.100992_bb0370","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K\u2013AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.blre.2022.100992_bb0375","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00109-015-1352-5","article-title":"Molecules in medicine mini-review: isoforms of PI3K in biology and disease","volume":"94","author":"Vanhaesebroeck","year":"2016","journal-title":"J Mol Med (Berl)"},{"issue":"11","key":"10.1016\/j.blre.2022.100992_bb0380","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2022.100992_bb0385","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjh.16879","article-title":"Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials","volume":"192","author":"Gordon","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2022.100992_bb0390","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.blre.2022.100992_bb0395","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper","volume":"37","author":"Cuneo","year":"2019","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.blre.2022.100992_bb0400","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am J Hematol"},{"issue":"35","key":"10.1016\/j.blre.2022.100992_bb0405","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2022.100992_bb0410","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/bloodadvances.2020001800","article-title":"The dual PI3K\u03b4\/CK1\u03b5 inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells","volume":"4","author":"Maharaj","year":"2020","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.blre.2022.100992_bb0415","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100992_bb0420","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood-2021-147918","article-title":"Efficacy and safety of parsaclisib in patients with relapsed or refractory follicular lymphoma: primary analysis from a phase 2 study (CITADEL-203)","volume":"138","author":"Lynch","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2022.100992_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2021.06.021","article-title":"Feasibility of combining the phosphatidylinositol 3-kinase inhibitor copanlisib with rituximab-based immunochemotherapy in patients with relapsed indolent B-cell lymphoma","volume":"21","author":"Matasar","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.blre.2022.100992_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30028-5","article-title":"Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials","volume":"4","author":"Smith","year":"2017","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.blre.2022.100992_bb0435","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"10232","key":"10.1016\/j.blre.2022.100992_bb0440","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"10277","key":"10.1016\/j.blre.2022.100992_bb0445","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet."},{"issue":"Supplement_1","key":"10.1016\/j.blre.2022.100992_bb0450","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2019-125394","article-title":"Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with Del(17p): initial results from Arm C of the Sequoia (BGB-3111-304) Trial","volume":"134","author":"Tam","year":"2019","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.blre.2022.100992_bb0455","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study","volume":"36","author":"Gopal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2022.100992_bb0460","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjh.16424","article-title":"The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma","volume":"189","author":"Fowler","year":"2020","journal-title":"Br J Haematol"},{"issue":"15_suppl","key":"10.1016\/j.blre.2022.100992_bb0465","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.1200\/JCO.2018.36.15_suppl.7549","article-title":"Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL)","volume":"36","author":"Fowler","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.blre.2022.100992_bb0470","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1200\/JCO.2022.40.16_suppl.7510","article-title":"Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial","volume":"40","author":"Zinzani","year":"2022","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.blre.2022.100992_bb0475","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100992_bb0480","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136219","article-title":"Ibrutinib and venetoclax in relapsed and refractory follicular lymphoma","volume":"136","author":"Ujjani","year":"2020","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2022.100992_bb0485","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.blre.2022.100992_bb0490","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.blre.2022.100992_bb0495","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2022.100992_bb0500","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2014.117473","article-title":"A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"100","author":"Chen","year":"2015","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.blre.2022.100992_bb0505","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.14698","article-title":"A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma","volume":"178","author":"Batlevi","year":"2017","journal-title":"Br J Haematol"},{"issue":"10254","key":"10.1016\/j.blre.2022.100992_bb0510","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.blre.2022.100992_bb0515","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2022.100992_bb0520","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.100992_bb0525","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1182\/blood-2021-148078","article-title":"Long-Term (\u22654 Year and \u22655 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)","volume":"138","author":"Jacobson","year":"2021","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2022.100992_bb0530","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.100992_bb0535","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2022.100992_bb0540","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.100992_bb0545","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2021-147913","volume":"138","author":"Kamdar","year":"2021","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2022.100992_bb0550","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.blre.2022.100992_bb0555","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2021.39.15_suppl.7515","volume":"39","author":"Jacobson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2022.100992_bb0560","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2021","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100992_bb0565","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2021-145025","article-title":"Efficacy of tisagenlecleucel in adult patients (Pts) with high-risk relapsed\/refractory follicular lymphoma (r\/r FL): subgroup analysis of the phase II elara study","volume":"138","author":"Thieblemont","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2022.100992_bb0570","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100992_bb0575","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2021-145872","article-title":"Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) who have received \u22652 prior lines of therapy: pivotal results from a Phase I\/II study","volume":"138","author":"Budde","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100992_bb0580","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase Ib study","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.blre.2022.100992_bb0585","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable Complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100992_bb0590","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2021-148778","article-title":"Glofitamab As monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R\/R) follicular lymphoma (FL)","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood."},{"issue":"10306","key":"10.1016\/j.blre.2022.100992_bb0595","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1016\/j.blre.2022.100992_bb0600","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1200\/JCO.2022.40.16_suppl.7524","article-title":"Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): Update from phase 1\/2 trial","volume":"40","author":"Falchi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2022.100992_bb0605","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood.2019004588","article-title":"Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study","volume":"136","author":"Lo","year":"2020","journal-title":"Blood."},{"issue":"31","key":"10.1016\/j.blre.2022.100992_bb0610","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2022.100992_bb0615","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/cncr.31374","article-title":"Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.blre.2022.100992_bb0620","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:28:14Z","timestamp":1759436894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22000662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":124,"alternative-id":["S0268960X22000662"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.100992","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Follicular lymphoma: The long and winding road leading to your cure?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.100992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100992"}}